Rapport Therapeutics, Inc. Common StockRAPPNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank67
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Latest
-31.02%
↑ 86% vs avg
Percentile
P67
Within normal range
Streak
2 yr
Consecutive growthAccelerating
Average
-220.40%
Historical baseline
PeriodValue
2025-31.02%
2024-133.31%
2023-717.27%
20220.00%